Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP and IV Gemcitabine with Radiotherapy and Surgery for Advanced Pancreatic Cancer
NCT00020345Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Sep 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by National Institutes of Health. Primary endpoints: Radiographic and/or Pathologic Response, Time to Disease Progression and 1 more. Started Sep 2000; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00020345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020345.